Lead Opinion
This case involves an appeal from an order of the district court denying defendant-appellant’s motion for sanctions under Fed.R.Civ.P. 11. For the reasons set forth below, we reverse and remand to the district court for the imposition of sanctions.
On September 21, 1983, attorneys for plaintiff-appellee Robin L. Albright filed this products liability action in the United States Distriсt Court for the Western District of Kentucky against nine pharmaceutical manufacturers and unknown defendants. On the same day, seven other actions were filed by the same attorneys on behalf of different plaintiffs against the same nine manufacturers. These defendants were involved in the manufacture, sale and distribution of tetracycline-based drugs, which allegedly had caused the permanent staining and discoloration of each plaintiff’s teeth. Litigation proceeded pursuant to Local Rule 19 governing complex litigation because the case involved more than five defendants.
In her complaint, Albright alleged that while an infant and during her teeth-forming years she ingested drugs which had a tetracycline base, and that said drugs were manufactured, publicized, distributed and sold by the named defendants and possible unknown defendants who may have been in the same business. She alleged that each of the defendants was strictly liable to her for all adverse consequences and injuries resulting from the use of said drugs. Al-bright further stated that she did not know the brand name or manufacturer of the рarticular drugs she ingested which caused discoloration of her teeth, “but one or more
Following the first pretrial conference, Upjohn and other defendants served Al-bright with interrogatories and а request for production of documents. Albright responded that “during her childhood and teeth-forming years she was prescribed by physicians various antibiotic drugs, including tetracyclines. The only brand names of such tetracycline drugs that Plaintiff is aware that she was prescribed and ingested is [sic] Tetrex, Declomycin, Myste-clin-F and this is by oral communication from Dr. Robert Kidd to Plaintiff’s mоther.” Attached to Albright’s answers to interrogatories were all medical records in her possession. The records of Dr. Kidd showed that he had prescribed for Albright between 1962 and 1967 the tetracycline-based drugs Tetrex, Declomycin and Mysteclin-F.
On June 8, 1984, Upjohn and four other defendants moved for summary judgment on the grounds that they had not been identified as manufacturers, distributors or sellers of any tetracycline drugs taken by Albright. On July 9, 1984, the court entered an order giving Albright sixty days within which to file an amended complaint. Albright never responded to the defendants’ motion for summary judgment. Instead, on August 28,1984, Albright filed an amended complaint in which only three tetracycline-based drug manufacturers were named as defendants. The three remaining defendants were the manufacturers of the tetracycline-based drugs prescribed to Albright by Dr. Kidd; these manufacturers had not joined in the motion for summary judgment. On September 13, 1984, the court granted Upjohn and its codefendants’ motion for summary judgment and dismissed all claims against them with prejudice. On September 24, 1984, Upjohn moved the court to alter the Septembеr 13th judgment to include an award of expenses, including attorney fees, pursuant to Federal Rule of Civil Procedure 11. The district court denied Upjohn’s motion to
Federal Rule of Civil Procedure 11, as amended effective August 1,1983, provides in part:
Every pleading, motion, and other paper of a party represented by an attorney shall be signed by at least one attorney of record in his individual name, whose address shall be stated____ The signature of an attorney or party constitutes a certificate by him that he has read the pleading, motion, or other paper; that to the best of his knowledge, information and belief formed after reasonable inquiry it is well grounded in fact and is warranted by existing law or a good faith argument for the extension, modification, or reversal of existing law, and that it is not interposed for any improper purpose, such as to harass or to cause unnecessary delay or needless increase in the cost of litigation. If a pleading, motion, or other paper is signed in violation of this rule, the court, upon motion or upon its own initiative, shall impose upon the person who signed it, a represented party, or both, an appropriate sanction, which may include an order to pay to the other party or parties the amount of the reasonable expenses incurred because of the filing of the pleading, motion, or other paper, including a reasonable attorney’s fee.
Appellant Upjohn argues that counsel for Albright violated Rule 11 by failing to conduct a reasonable prefiling investigation of the facts. Upjohn points out that counsel for Albright received the relevant medical records from Dr. Kidd in November 1982, and at that time became aware that Al-bright had ingested Tetrex, Declomycin and Mysteclin-F. Upjohn suggests that Al-bright’s attorneys had ample time to investigate her claim because eleven months elapsed from the time Albright’s cause of action accrued and the date the complaint was filed, and medical records were obtained from Dr. Kidd ten months before filing; Upjohn asserts that the intervening time period was sufficient to locate any other medical records or to confirm their nonexistence. Upjohn states that the information needed to identify the proper defendants in this case was not confusing or complex, and that the three attorneys who signed the complaint were experienced litigators who had prosecuted other tetracycline products liability actions. Thus, Upjohn urges, an adequate prefiling investigation could have been conducted without much difficulty. Upjohn submits that Al-bright’s attorneys intentionally shifted both the burden of proof as well as the cost of product identification to the defendants. Upjohn claims that the failure of Albright’s counsel to cоnduct reasonable prefiling inquiry has caused Upjohn unnecessary litigation expenses and resulted in a delay of discovery for the remaining parties.
Albright
Upjohn responds that merely because seven other similar cases were filed on the same day does not excuse Albright’s attorneys from meeting the demands of Rule 11. Finally, Upjohn asserts that just because it had been a defendant in other tetracycline suits did not relieve Albright’s attorneys of their obligation to investigate whether Upjohn was a proper defendant in the instant action.
Rule 11 was amended in 1983 “to' reduce the reluctance of courts to impose sanctions____by emphasizing the responsibilities of the attorney and reenforcing thоse obligations by the imposition of sanctions.” Advisory Committee Note, Fed.R. Civ.P. 11. “The new language stresses the need for some prefiling inquiry into both the facts and the law to satisfy the affirmative duty imposed by the rule. The standard is one of reasonableness under the circumstances. See Kinee v. Abraham Lincoln Fed. Sav. & Loan Ass’n,
Notes
. Tetrex was manufactured by defendant Bristol Laboratories, Declomycin was a product of defendant Lederle Laboratories, and defendant E. R. Squibb and Sons manufactured Mysteclin-F.
. Terramycin was defendant Pfizer, Inc.’s tetracycline product. (Pfizer, Inc. was not named as a defendant in Albright’s amended complaint, apparently because she was prescribed the drug after her teeth-forming years.)
. The district court first stated that the denial of the motion to amend was not a final and appeal-able order, but later vacated its original order and granted Upjohn’s motion to amend to include a recitation of finality so that Upjohn could appeal the denial of the motion for sanctions under Fed.R.Civ.P. 11.
. Although Albright is the named plaintiff-appel-lee, sanctions for a violation of Rule 11 are to be imposed upon the person who signed the complaint, a represented party, or both. Amended Rule 11 “should eliminate any doubt as to the propriety of assessing sanctions against the attorney." Advisory Committee Note, Fed. R.CÍV.P. 11.
. Albright also asserts that she was justified in pleading concert of action, alternate liability or joint enterprise theories of liability because such theories were "warranted by existing law or а good faith argument for the extension, modification or reversal of existing law,” citing Sindell v. Abbott Laboratories,
. In Kinee, plaintiffs’ attorneys sued every individual or lending institution listed in the Philadelphia phone book under the heading of mortgage broker or related headings.
. The complaint was filed in September 1983, and the defendants’ motion for summary judgment was filed on June 8, 1984. Albright did not file an amended complaint until August 24, 1984, when, as she states in her brief, “she finally found all the specific Defendants she could find____’’ Albright asserted her claim for liability against Upjohn with the knowledge that she had no factual basis for the claim, and continued to assert the claim long after it would have been reasonablе to have dismissed it.
. The dissenting opinion suggests that proper resolution of this issue lies under Fed.R.Civ.P. 41(a). However, dismissal thereunder is specifically limited to situations where a signed stipulation or a motion for dismissal has been filed, neither of which occurred here.
Dissenting Opinion
dissenting.
Although dissenting, my difference with the majority is more one of degree than of kind. There is no disagreement that sanctions are now mandatory under Rule 11 if & violation is found. Our problem on review of this matter is complicated by the fact that the trial court made no findings but simply denied the motion for Rule 11 sanctions. If the court had made factual findings, these would be reviewable under the “clearly erroneous” standard. Taylor and Gaskin, Inc. v. Chris Craft Industries,
I simply do not believe that we have enough evidencе before us that we can sanction plaintiff’s counsel in this case. Had the majority merely remanded for hearing at which factual findings could be developed, I would have readily concurred.
I believe there is another resolution for this particular case, however, that would have made the defendant whole for its costs without the necessity of finding a violation of the rules. Rule 41(a) provides that after a party has filed either an answer or a motion for summary judgment a plaintiff may not dismiss as to that party without order of the court or by stipulation with all parties who have appeared. In this case, defendant Upjohn filed a summary judgment motion. Subsequent to the filing of that summary judgment motion, the plaintiff, rather than rеsponding to the summary judgment motion, filed an amended complaint dropping Upjohn from the case. Under such circumstances, the plaintiff needed the court’s permission to dismiss Upjohn, and Rule 41(a)(2) provides that such permission may be “upon such terms and conditions as the court deems proper.” Upjohn was not a proper defendant in this case. In оrder to remove itself from the case, Upjohn had to spend money for costs and attorney’s fees. It should be reimbursed for those costs. Where one of two innocent parties has to suffer, it should be the one who puts the wheels in motion, and in this case that was the plaintiff. Where the issue is dismissing as to an inappropriately named defendant, under the circumstances presented here, I would prefer to see resolution by using Rule 41(a)(2) as opposed to the imposition of a sanction unless it is clear that a violation of Rule 11 has occurred. I recognize, of course, that there are many situations in which this method of disposition would not be appropriate or applicable. Howevеr, it would appear to me to fit perfectly the situation with which we are here dealing.
. The parties and the court are in agreement that the standard used in evaluating an alleged Rule 11 violation is an objective one. Therefore, a court does not need to find willfulness as such. However, the trial court’s analysis of where the alleged offending party’s conduct falls on a continuum ranging from simple negligence to willfulness will undoubtedly be part of the equation.
